Daniele Tramontano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Daniele Tramontano has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
Marcello Arca
Department of Translational and Precision Medicine, Sapienza University of Rome, Viale Dell' Università 37, 00161, Rome, Italy
5 shared publications- Laura D'ERasmo
Department of Translational and Precision Medicine, Sapienza University of Rome, 00161 Rome, Italy
4 shared publications Alessia Di Costanzo
Department of Translational and Precision Medicine, Sapienza University of Rome, Viale Dell' Università 37, 00161, Rome, Italy
3 shared publications- Alessia Di Costanzo
Department of Translational and Precision Medicine, Sapienza University of Rome, 00161 Rome, Italy
3 shared publications Daniela Commodari
Department of Translational and Precision Medicine, Sapienza University of Rome, Viale Dell' Università 37, 00161, Rome, Italy
3 shared publicationsIlenia Minicocci
Department of Translational and Precision Medicine, Sapienza University of Rome, Viale Dell' Università 37, 00161, Rome, Italy
3 shared publications
Latest Publications
- Open Access
- 20 October 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (10) , 1531
A Nutrient-Dependent ANGPTL3–PCSK9-Containing Complex in HepG2 Cells and Human Plasma
ANGPTL3 and PCSK9 are key regulators of lipoprotein metabolism, with emerging evidence suggestive of a functional regulatory interrelationship. Indeed, patients lacking ANGPTL3 due to loss-of-function variants exhibit reduced circulating PCSK9 levels. This study aimed to determine whether ANGPTL3 and PCSK9 are part of the same complex. Co-immunoprecipitation (Co-IP) experiments in HepG2 cells and human plasma assessed whether ANGPTL3 and PCSK9 co-immunoprecipitated. A hypothetical interaction between the two proteins was also modeled in silico using two software packages: AlphaFold2 and ZDOCK. HepG2 cells overexpressing ANGPTL3, PCSK9, and ANGPTL3-PCSK9 were generated to investigate the relationship between ANGPTL3 and PCSK9 under different nutrient conditions. Reciprocal Co-IP experiments in HepG2 cells and human plasma showed that ANGPTL3 and PCSK9 could be recovered in the same co-immunoprecipitated sample, both intracellularly and in the culture medium. Structural modeling supported the experimental observations and identified a 2:1 ANGPTL3:PCSK9 arrangement as a plausible configuration. We observed higher association under fasting conditions and lower association under simulated feeding conditions. The latter was also confirmed in postprandial human plasma, where ANGPTL3 is known to bind ANGPTL8 in a 2:1 complex. Moreover, incubation of HepG2 cells with LDL appeared to reduce ANGPTL3-PCSK9 association. In summary, our study identifies a dynamic ANGPTL3–PCSK9 association that is regulated in a nutrient-dependent fashion. These findings may broaden current understanding of ANGPTL3 and PCSK9 biology and support further mechanistic studies, particularly in the context of therapeutic inhibition of these proteins.
- 20 October 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (10) , 1531
Open AccessA Nutrient-Dependent ANGPTL3–PCSK9-Containing Complex in HepG2 Cells and Human Plasma
ANGPTL3 and PCSK9 are key regulators of lipoprotein metabolism, with emerging evidence suggestive of a functional regulatory interrelationship. Indeed, patients lacking ANGPTL3 due to loss-of-function variants exhibit reduced circulating PCSK9 levels. This study aimed to determine whether ANGPTL3 and PCSK9 are part of the same complex. Co-immunoprecipitation (Co-IP) experiments in HepG2 cells and human plasma assessed whether ANGPTL3 and PCSK9 co-immunoprecipitated. A hypothetical interaction between the two proteins was also modeled in silico using two software packages: AlphaFold2 and ZDOCK. HepG2 cells overexpressing ANGPTL3, PCSK9, and ANGPTL3-PCSK9 were generated to investigate the relationship between ANGPTL3 and PCSK9 under different nutrient conditions. Reciprocal Co-IP experiments in HepG2 cells and human plasma showed that ANGPTL3 and PCSK9 could be recovered in the same co-immunoprecipitated sample, both intracellularly and in the culture medium. Structural modeling supported the experimental observations and identified a 2:1 ANGPTL3:PCSK9 arrangement as a plausible configuration. We observed higher association under fasting conditions and lower association under simulated feeding conditions. The latter was also confirmed in postprandial human plasma, where ANGPTL3 is known to bind ANGPTL8 in a 2:1 complex. Moreover, incubation of HepG2 cells with LDL appeared to reduce ANGPTL3-PCSK9 association. In summary, our study identifies a dynamic ANGPTL3–PCSK9 association that is regulated in a nutrient-dependent fashion. These findings may broaden current understanding of ANGPTL3 and PCSK9 biology and support further mechanistic studies, particularly in the context of therapeutic inhibition of these proteins.
- Open Access
- 4 February 2026
- Published by Elsevier in Atherosclerosis
- Vol. 413, 120621
The hidden burden of kidney damage in chylomicronemia syndromes
- 4 February 2026
- Published by Elsevier in Atherosclerosis
- Vol. 413, 120621
Open AccessThe hidden burden of kidney damage in chylomicronemia syndromes
- Open Access
- 1 December 2025
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 45 (12) , 2264-2276
Contemporary Management of Familial and Multifactorial Chylomicronemia Syndromes in Italy: Insights From the National LIPIGEN Registry
BACKGROUND: We aimed to compare the molecular and clinical characteristics of patients identified in Italy as affected by either familial chylomicronemia syndrome (FCS) or multifactorial chylomicronemia syndrome (MCS) and to assess the overall benefit of novel triglyceride-lowering therapies prescribed to these patients within the routine clinical care. METHODS: From the national LIPIGEN-sHTG (Lipid Transport Disorders Italian Genetic Network—Severe Hypertriglyceridemia) registry, 169 patients (57 FCS, 51 MCS, 61 variant-negative, variant-negative MCS) were retrospectively analyzed. Data on clinical and genetic characteristics, medical history, and medications were collected. Peak triglyceride levels were used to define untreated lipid phenotypes. RESULTS: In FCS, 72% exhibited biallelic LPL and 28% non-LPL variants; in MCS, 38% (n=19) carried LPL variants, and 38% (n=19) carried APOA5 variants, whereas the remaining individuals were carriers of LMF1 (n=3), GPIHBP1 (n=2), and CREB3L3 or GPD1 variants (n=8), respectively. Peak TGs were highest in FCS (3000 mg/dL [interquartile range, 2116.0–4265.0]), followed by MCS (1817 mg/dL [interquartile range, 1370.0–3062.0]) and variant-negative MCS (1340.0 mg/dL [interquartile range, 946.5–2508.5]; P LPL variants. Lomitapide and volanesorsen provide better triglyceride control, yet only one-third of FCS were treated with these drugs in the routine clinical practice.
- 1 December 2025
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 45 (12) , 2264-2276
Open AccessContemporary Management of Familial and Multifactorial Chylomicronemia Syndromes in Italy: Insights From the National LIPIGEN Registry
BACKGROUND: We aimed to compare the molecular and clinical characteristics of patients identified in Italy as affected by either familial chylomicronemia syndrome (FCS) or multifactorial chylomicronemia syndrome (MCS) and to assess the overall benefit of novel triglyceride-lowering therapies prescribed to these patients within the routine clinical care. METHODS: From the national LIPIGEN-sHTG (Lipid Transport Disorders Italian Genetic Network—Severe Hypertriglyceridemia) registry, 169 patients (57 FCS, 51 MCS, 61 variant-negative, variant-negative MCS) were retrospectively analyzed. Data on clinical and genetic characteristics, medical history, and medications were collected. Peak triglyceride levels were used to define untreated lipid phenotypes. RESULTS: In FCS, 72% exhibited biallelic LPL and 28% non-LPL variants; in MCS, 38% (n=19) carried LPL variants, and 38% (n=19) carried APOA5 variants, whereas the remaining individuals were carriers of LMF1 (n=3), GPIHBP1 (n=2), and CREB3L3 or GPD1 variants (n=8), respectively. Peak TGs were highest in FCS (3000 mg/dL [interquartile range, 2116.0–4265.0]), followed by MCS (1817 mg/dL [interquartile range, 1370.0–3062.0]) and variant-negative MCS (1340.0 mg/dL [interquartile range, 946.5–2508.5]; P LPL variants. Lomitapide and volanesorsen provide better triglyceride control, yet only one-third of FCS were treated with these drugs in the routine clinical practice.
- Open Access
- 4 November 2025
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 20 (1) , 104-111
Long-term efficacy and safety of lomitapide in patients with familial chylomicronemia syndrome: Data from an expanded access program
- 4 November 2025
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 20 (1) , 104-111
Open AccessLong-term efficacy and safety of lomitapide in patients with familial chylomicronemia syndrome: Data from an expanded access program
- Open Access
- 15 May 2025
- Published by Elsevier in Journal of Clinical Lipidology
Lomitapide-induced fatty liver is a reversible condition: Evidence from a case of familial chylomicronemia syndrome
- 15 May 2025
- Published by Elsevier in Journal of Clinical Lipidology
Open AccessLomitapide-induced fatty liver is a reversible condition: Evidence from a case of familial chylomicronemia syndrome
- Open Access
- 19 March 2025
- Published by Springer Nature in Drugs
- Vol. 85 (6) , 755-775
Renal Safety Assessment of Lipid-Lowering Drugs: Between Old Certainties and New Questions
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in patients with chronic kidney disease (CKD). Quantitative and qualitative changes in plasma lipoprotein profiles are frequently associated with CKD and represent a significant risk factor for CVD in patients with CKD. Guidelines from the European Society of Cardiology and the European Atherosclerosis Society classify CKD as a condition with high or very high cardiovascular risk and set specific low-density lipoprotein cholesterol targets. Conventional lipid-lowering therapies (LLTs), such as statins, ezetimibe, and fibrates, can control CKD-associated dyslipidemia and, to some extent, prevent major atherosclerotic events in patients with CKD, but their use in clinical practice presents challenges because of the potential renal safety concerns. In recent years, novel therapies with the ability to lower both low-density lipoprotein cholesterol and triglycerides have been introduced to the market (e.g., proprotein convertase subtilisin/kexin type 9 inhibitors, bempedoic acid, lomitapide, volanesorsen) to improve our ability to control lipid abnormalities. However, their impact on kidney functionality has not been fully elucidated. The aim of this review was to examine the renal safety profiles of various LLTs, with special reference to novel medications, and to highlight important considerations and guidance for the use of these medications in overt CKD or in patients with some degree of renal function impairment. We underscore the lack of a comprehensive understanding of kidney safety, particularly for novel LLT therapies, and strongly emphasize the importance of future dedicated research to fully assess the safety and efficacy of these agents in patients with kidney abnormalities.
- 19 March 2025
- Published by Springer Nature in Drugs
- Vol. 85 (6) , 755-775
Open AccessRenal Safety Assessment of Lipid-Lowering Drugs: Between Old Certainties and New Questions
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in patients with chronic kidney disease (CKD). Quantitative and qualitative changes in plasma lipoprotein profiles are frequently associated with CKD and represent a significant risk factor for CVD in patients with CKD. Guidelines from the European Society of Cardiology and the European Atherosclerosis Society classify CKD as a condition with high or very high cardiovascular risk and set specific low-density lipoprotein cholesterol targets. Conventional lipid-lowering therapies (LLTs), such as statins, ezetimibe, and fibrates, can control CKD-associated dyslipidemia and, to some extent, prevent major atherosclerotic events in patients with CKD, but their use in clinical practice presents challenges because of the potential renal safety concerns. In recent years, novel therapies with the ability to lower both low-density lipoprotein cholesterol and triglycerides have been introduced to the market (e.g., proprotein convertase subtilisin/kexin type 9 inhibitors, bempedoic acid, lomitapide, volanesorsen) to improve our ability to control lipid abnormalities. However, their impact on kidney functionality has not been fully elucidated. The aim of this review was to examine the renal safety profiles of various LLTs, with special reference to novel medications, and to highlight important considerations and guidance for the use of these medications in overt CKD or in patients with some degree of renal function impairment. We underscore the lack of a comprehensive understanding of kidney safety, particularly for novel LLT therapies, and strongly emphasize the importance of future dedicated research to fully assess the safety and efficacy of these agents in patients with kidney abnormalities.
- Open Access
- 30 April 2023
- Published by S.I.Te.C.S Societa Italiana di Terapia Clinica e Sperimentale in European Atherosclerosis Journal
- Vol. 2 (1) , 25
Thrombocytopenia and Kidney disease, two possible hallmark of FCS phenotype: preliminary evidence from a cohort study
Background and Aim: Familial Chylomicronemia Syndrome (FCS) is a rare monogenic autosomal recessive disorder of lipid metabolism determining severe hypertriglyceridemia (HTG). As the use of Volanesorsen, a novel FCS treating drug, has been associated with thrombocytopenia, the relationship between FCS and low platelets counts should be firmly established. It has been reported also kidney complication in FCS, but the data are sparse. To this aim, we have retrospectively evaluated the spontaneous variation of platelet counts and Kidney impairment in a cohort of patients with FCS. Methods: Single-center retrospective cohort study on 20 FCS patients included in the LIPIGEN. Medical charts have been revised to collect retrospectively information on kidney function in a cohort of patients with FCS. Results: Across the study population, the median PLT count was 187,225 platelet/mcL. The median on treatment TG levels in the whole cohort was 1309 mg/dl. During follow-up, 8 (44.4%) patients experienced at least one episode of mild and 1 (5%) of moderate thrombocytopenia. None had severe thrombocytopenia. Mean triglycerides do not significantly predict mean platelet values. However, when considering a multivariate model including mean triglycerides, sex, the presence of hepatic steatosis and age we found that male sex and the presence of ultrasound estimated hepatic steatosis were associated with significantly lower platelet (respectively β-0,473, P=0,044 and β-0,469, P=0,048). Age was of borderline statistical significance (β-0,388, P=0,087). Across the study population, the median GFR values was 99.5 ml/min. Median eGFR was significantly associated with history of hypertension (β-0,508, P=0,031). Overall, proteinuria occurred in 5 (25%) patients, and it did not associate with hypertension, diabetes, age, sex nor triglyceride levels. Four (20.0%) patients meet the criteria of hyperfiltration whereas 3 (15.0%) were exhibiting an eGFR below 90 ml/min. Among hyperfiltrating, two had also proteinuria in at least one occasion during life. One patient with eGFR below 90 ml/min and proteinuria had a biopsy-proven diagnosis of glomerulonephritis. Overall, the impairment in kidney function was independent from age, diabetes, hypertension, median TGs, AP, sex. Conclusions: The present analysis confirmed that thrombocytopenia and kidney impairment might be a clinical characteristics of FCS phenotype. Further studies in larger cohort are needed to better clarify if kidney disease and thrombocytopenia might be a hallmark of FCS in broader population and understand the potential patho-physiological mechanism.
- 30 April 2023
- Published by S.I.Te.C.S Societa Italiana di Terapia Clinica e Sperimentale in European Atherosclerosis Journal
- Vol. 2 (1) , 25
Open AccessThrombocytopenia and Kidney disease, two possible hallmark of FCS phenotype: preliminary evidence from a cohort study
Background and Aim: Familial Chylomicronemia Syndrome (FCS) is a rare monogenic autosomal recessive disorder of lipid metabolism determining severe hypertriglyceridemia (HTG). As the use of Volanesorsen, a novel FCS treating drug, has been associated with thrombocytopenia, the relationship between FCS and low platelets counts should be firmly established. It has been reported also kidney complication in FCS, but the data are sparse. To this aim, we have retrospectively evaluated the spontaneous variation of platelet counts and Kidney impairment in a cohort of patients with FCS. Methods: Single-center retrospective cohort study on 20 FCS patients included in the LIPIGEN. Medical charts have been revised to collect retrospectively information on kidney function in a cohort of patients with FCS. Results: Across the study population, the median PLT count was 187,225 platelet/mcL. The median on treatment TG levels in the whole cohort was 1309 mg/dl. During follow-up, 8 (44.4%) patients experienced at least one episode of mild and 1 (5%) of moderate thrombocytopenia. None had severe thrombocytopenia. Mean triglycerides do not significantly predict mean platelet values. However, when considering a multivariate model including mean triglycerides, sex, the presence of hepatic steatosis and age we found that male sex and the presence of ultrasound estimated hepatic steatosis were associated with significantly lower platelet (respectively β-0,473, P=0,044 and β-0,469, P=0,048). Age was of borderline statistical significance (β-0,388, P=0,087). Across the study population, the median GFR values was 99.5 ml/min. Median eGFR was significantly associated with history of hypertension (β-0,508, P=0,031). Overall, proteinuria occurred in 5 (25%) patients, and it did not associate with hypertension, diabetes, age, sex nor triglyceride levels. Four (20.0%) patients meet the criteria of hyperfiltration whereas 3 (15.0%) were exhibiting an eGFR below 90 ml/min. Among hyperfiltrating, two had also proteinuria in at least one occasion during life. One patient with eGFR below 90 ml/min and proteinuria had a biopsy-proven diagnosis of glomerulonephritis. Overall, the impairment in kidney function was independent from age, diabetes, hypertension, median TGs, AP, sex. Conclusions: The present analysis confirmed that thrombocytopenia and kidney impairment might be a clinical characteristics of FCS phenotype. Further studies in larger cohort are needed to better clarify if kidney disease and thrombocytopenia might be a hallmark of FCS in broader population and understand the potential patho-physiological mechanism.